Abstract
A prospective, randomised, observer-blind, comparative study was performed in healthy adults with a new hepatitis A/typhoid combined vaccine. Viatim(TM), and the marketed Hepatyrix(TM) vaccine. Both vaccines induced high levels of protective antibodies, but typhoid responses were higher and hepatitis A responses more rapid with Viatim(TM) compared with Hepatyrix(TM). Both vaccines were well tolerated, no serious adverse events (SAEs) occurred, but more Viatim(TM) vaccinees had more mild or moderate local reactions (82.7%) than Hepatyrix(TM) (53.1%, p < 0.001). In this direct comparison Viatim(TM) induced more local reactions, but elicited a more rapid and higher immune response to both antigens than Hepatyrix(TM). (C) 2004 Elsevier Ltd. All rights reserved.
| Original language | English |
|---|---|
| Pages (from-to) | 29-35 |
| Number of pages | 7 |
| Journal | Vaccine |
| Volume | 23 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 15 Nov 2004 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Combined vaccine
- Hepatitis A
- Typhoid
Fingerprint
Dive into the research topics of 'Comparison of two combined vaccines against typhoid fever and hepatitis A in healthy adults'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver